DCA Unearths Spurious Medicine Racket In Vijayawada

Vijaywada : The Department of Drugs Control Administration of the State government has busted a spurious drug racket in Vijayawada.

The Drugs Inspector has established that certain drugs manufactured by reputed pharma companies are imitated, and manufactured in a manner that would deceive unsuspecting consumers. The department further learnt that the unauthorised dealers are supplying substandard medicines by falsely labelling them as products manufactured by a reputed pharma company.

These counterfeit and spurious drugs would cause severe and fatal damage to one’s health as they are not manufactured by the original drug companies. The materials used in the drugs and the conditions being maintained at the manufacturing facility are of dubious quality, and it is likely that the ingredients can be toxic and can even cause death, said B. Anvesh Reddy, Drugs Inspector, Vijayawada Zone-IV of the Drug Control Administration in his complaint lodged with the Bhavanipuram police in Vijayawada on September 6 (Wednesday). The Hindu has accessed the complaint of the Drugs Inspector, a copy of the First Information Report (FIR) and other laboratory findings related to the drug racket.

The FIR has been registered against P.D.M.K.R.G. Krishna Murthy, of Lakshmi Padmavathi Pharma at Vasavi Pharma Market Complex in Vijayawada, and N. Kiran Kumar of Vidyadharapuram in Vijayawada under Sections 420 (cheating and dishonestly inducing delivery of property), 471 (using as genuine a forged document), 274 (adulteration of drugs) and 275 (selling adulterated drugs) of the Indian Penal Code (IPC).

Related Posts

  • Pharma
  • June 17, 2025
  • 99 views
Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…

  • Pharma
  • June 17, 2025
  • 102 views
Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd on Monday announced the appointment of Swati Dalal as an additional director and Managing Director of its wholly-owned arm Zydus Healthcare Ltd. The board of Zydus Healthcare…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Zydus Healthcare appoints Swati Dalal MD

Zydus Healthcare appoints Swati Dalal MD

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco API plant gets one observation from FDA

Natco API plant gets one observation from FDA